Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Affymax's Share Price Stumbles On Questionable Phase III Hematide Data

This article was originally published in The Pink Sheet Daily

Executive Summary

Phase III data for Affymax/Takeda's anemia drug for chronic kidney failure signals potential regulatory hurdles in non-dialysis use.

You may also be interested in...



Affymax Plans For Peginesatide Launch

The biotech is making plans with its Japanese partner for the launch of its new ESA that is awaiting approval.

Affymax Plans For Peginesatide Launch

The biotech is making plans with its Japanese partner for the launch of its new ESA that is awaiting approval.

CMS Begins National Coverage Determination Process For ESAs In The Renal Setting

The opening of a national coverage analysis comes with a public request for CMS to establish Medicare coverage limitations for ESA use in pre-dialysis and dialysis renal disease patient populations.

Related Content

Topics

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel